UK markets closed

Abingdon Health Plc (ABDX.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
55.50-0.50 (-0.89%)
At close: 6:41PM BST
Full screen
Previous close56.00
Open58.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range53.25 - 58.00
52-week range0.81 - 136.65
Volume916,157
Avg. volume622,654
Market cap53.113M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Abingdon Health Notes Announcement by UK-RTC on providing an Antibody Certificate using smartphone App technology

    Abingdon Health Notes Announcement by UK-RTC on providing an Antibody Certificate using smartphone App technology The Antibody Certificate Solution will provide a tool to support the opening of economies and a return to normal life York, U.K. 19 April 2021: Abingdon Health plc (AIM: ABDX) (“the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, welcomes the announcement today by the UK Rapid Test Consortium (UK-RTC) that the AbC-19™ rapid test is now paired with an easy-to-use mobile app which allows a trained professional to generate an antibody certificate on a person’s smartphone. The AbC-19™ rapid test is a very easy-to-use, accurate and reliable neutralising antibody test indicating recovery post infection or presence of neutralising antibodies post vaccine. Testing can take place in a wide range of environments such as at a high-street pharmacy or workplace testing by a trained user. Whilst performing the test, the trained user takes a picture of the individual to create a secure antibody certificate. Based on the Apple and Google approach for boarding passes, users will not need to install any new apps thanks to the new feature being built using a trusted existing interface compatible with all smartphones. The QR code will be stored in the wallet feature of the smartphone, allowing the individual to control access to their personal results. The antibody certificate solution has been developed by BBI Solutions, a member of the UK-RTC, using their Novarum™️ technology. Neil Polwart Head of Mobile Solutions at BBI said: “As diagnostics moves ever closer to the patient, we saw a new challenge of enabling the patient to carry their test result with them. We wanted to do this in a way which would not require the patient to install any new apps or anyone checking the certificate to need special software, so that people could be assured we had privacy as the priority.” For more information please contact: Abingdon Health plc info@abingdonhealth.com +44 (0) 1904 406082 Leigh Thomas, SVP Director of Global Sales of Abingdon Health Consilium Strategic Communications +44 (0) 203 709 5700 abingdonhealth@consilium-comms.com Matthew Neal Mary-Jane ElliottLindsey Neville About the UK-RTC The UK Rapid Test Consortium (UK-RTC) was founded in response to a UK Government call for businesses to work together on a rapid antibody test to be rolled out nationally. Led by Abingdon Health, it’s members also include, BBI Solutions, CIGA Healthcare and Omega Diagnostics. The Abc-19TM is approved in Europe and the UK for professional use and is available for sale. About the AbC-19™ Rapid Test The AbC-19™ Rapid Test is a single use test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus in human capillary whole blood. About Abingdon Health plcAbingdon Health plc is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. Founded in 2008, Abingdon Health is headquartered in York, England. www.abingdonhealth.com/

  • AbC-19™ Rapid Test used in UK BioBank COVID-19 Antibody Study
    Globe Newswire

    AbC-19™ Rapid Test used in UK BioBank COVID-19 Antibody Study

    AbC-19™ Rapid Test used in UK BioBank COVID-19 Antibody Study The study will investigate the long-term health effects of long COVID York, U.K. 29 March 2021: The UK-RTC is pleased to announce that the AbC-19™ rapid neutralising antibody test is being deployed in Phase 2 of the UK Biobank Coronavirus self-test antibody study. The study will provide researchers with unique opportunities to investigate the long-term health effects of SARS-CoV-2 infection (“long COVID”) and other health research related to COVID-19. The AbC-19™ Rapid Test is being utilised in Phase 2 of the study, which initiated in March 2021. Further details of the study can be found on the UK BioBank website. Participants will be sent the AbC-19™ test as part of a finger-prick home-testing kit that is simple and quick to do, returning results within 20 minutes. The results can then be submitted via the UK Biobank website. The test results and questionnaire data provided by participants will be incorporated into the UK Biobank resource and made available to approved researchers for vital COVID-19 research. The AbC-19™ Rapid Test is a single use test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus. The test has been developed by the UK Rapid Test Consortium (UK-RTC) of which Abingdon Health is the lead member. Prof. Chris Molloy, Independent Chair of the UK-RTC, commented: “Our consortium developed the AbC-19™ test to enable large-scale, mass testing - providing rapid, accurate results for researchers and citizens alike. It is testament to its quality that AbC-19™ is being used to support this national-scale research programme into the genetic and clinical risk factors for long COVID disease. We have much to learn about the role of antibodies in disease protection, and the long-term effects of the disease, which makes AbC-19™ a critical tool today and into the future.” The UK Biobank is a large-scale biomedical database and research resource which contains in-depth genetic and health information from 500,000 UK participants. The database contributes to the advancement of modern medicine and enables scientific discoveries that improve human health. For more information please contact: Abingdon Health plc +44 (0) 1904 406082 Leigh Thomas, SVP Director of Global Sales of Abingdon Health info@abingdonhealth.com Consilium Strategic Communications +44 (0) 203 709 5700 Mary-Jane Elliott abingdonhealth@consilium-comms.com Matthew NealLindsey Neville About the AbC-19™ Rapid Test The Company has developed and is manufacturing the AbC-19™ Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.

  • Globe Newswire

    Webinar: The role of antibody testing as a companion test to SARS-CoV-2 vaccination

    Webinar: The role of antibody testing as a companion test toSARS-CoV-2 vaccination York, U.K. 10 March 2021: Abingdon Health plc, a leading international developer and manufacturer of high quality and effective rapid tests, will present a webinar entitled ‘The role of antibody testing as a companion test to SARS-CoV-2 vaccination’ in partnership with Fierce Pharma on Thursday 1st April. The nature of testing for the SARS-CoV-2 virus has changed over the course of the pandemic. Once, antibody tests were predominantly used for charting the spread of infection within communities, but today they are emerging as a key pillar of large-scale immunisation campaigns. Abingdon’s own antibody test for the virus, the AbC-19™ Rapid Test, is a self-contained, highly accurate lateral flow immunoassay designed to give results within 20 minutes at the point of use. Attendees are invited to join Abingdon Health and an expert panel to discuss new data demonstrating the key roles antibody testing has to play, which will foster discussions on understanding longevity of immunity and provide the opportunity to examine the rationale of pre-screening people for antibodies prior to vaccination. The data will enable examination of antibody vaccine response using rapid neutralising antibody tests. The webinar will allow viewers to: Learn about the importance of neutralising rapid antibody detection and vaccine role outGain insight into how patients respond to COVID-19 vaccinesDiscover the longevity of neutralising antibodies following infection with the SARS-CoV-2 virusReview the performance characteristics and usability of rapid antibody tests Panellists include key academic leaders alongside Abingdon Health: Professor Mark Drayson, Clinical Immunologist, University of Birmingham, UKProfessor Tara Moore, Professor of Personalised Medicine, Ulster University, NIProfessor Lawrence S. Young, Virologist and Pro-Dean for External Affairs, Warwick Medical School and Director of the Warwick Cancer Research Centre, UKNina Garrett, R&D Director, Abingdon Health, UK Register now online to confirm your interest and receive access details. For more information please contact: Abingdon Health plc +44 (0) 1904 406082 Leigh Thomas, SVP Director of Global Sales of Abingdon Health info@abingdonhealth.com Consilium Strategic Communications +44 (0) 203 709 5700 Matthew Neal abingdonhealth@consilium-comms.com Mary-Jane ElliottLindsey Neville About Abingdon Health plcAbingdon Health plc is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world.. Founded in 2008, Abingdon Health is headquartered in York, England. www.abingdonhealth.com/ AbC-19TM Rapid TestThe Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.